Flatiron Health today announced that the company will present a total of six abstracts accepted for oral and poster presentation at this year’s American Society of Hematology (ASH) Annual Meeting, to be held in San Diego, CA this December 9-12. Flatiron's research and presence at this global scientific forum driving progress in hematologic oncology showcases our commitment to innovative research and the potential of advanced AI-methodologies and real-world data to answer questions for complex and rare diseases.
“Our presence at this year’s ASH Annual Meeting leverages our Flatiron technology to not only learn more from patients with hematologic malignancies, but also to break barriers for rare populations to advance research and access to clinical trials.” said Javier Jimenez, Chief Medical Officer, Flatiron Health. “Our use of innovative research methods, including AI, allow us to scale the impact of our real-world data and generate insights for diverse patient populations, driving the critical research needed to close the gap between care and research.”
Research highlights include:
-
An Oral Presentation utilizing machine learning to examine the clinical characteristics, treatment trends, and outcomes of patients with rare HHV-8-negative/idiopathic multicentric Castleman disease treated with siltuximab.
-
An Oral Presentation validating the performance of newer staging systems, MASS and R2-ISS, for a large, contemporary cohort of myeloma patients in the United States.
-
A Oral Presentation exploring the real-world usage and effectiveness of once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma.
Learn more about our abstracts and events by visiting our event website.
Follow Flatiron Health on Twitter and LinkedIn for more updates from #ASH23.
Poster Discussions and Presentations
Clinical Characteristics, Treatment Trends, and Outcomes of Patients with HHV-8-Negative/Idiopathic Multicentric Castleman Disease Treated with Siltuximab in a Machine Learning-Selected Real-World Cohort
Oral Presentation
Aaron Cohen, Melissa Estevez, Jack Kelly, James Gippetti, Erin Fidyk, Josh Bradstater, Dave Fajgenbaum
Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States
Oral Presentation
Gregory Calip, Xiaoyan Wang, Christina Parrinello
Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma
>Oral Presentation
Wendy Wang, James Roose
Low Socioeconomic Status Confers Poorer Real-World Overall Survival for Patients with Acute Myeloid Leukemia Treated in the Modern Era
Poster Presentation
Mark Guinter, Brendan Kerr, Gregory Calip, Anita J. Kumar, Ahmed Sawas
Inequities in Autologous Stem Cell Transplantation, Chimeric Antigen Receptor T-Cell Therapy and Clinical Trial Participation in Patients Receiving Second-Line and Later Multiple Myeloma Treatment
Poster Presentation
Amy Pierre, Gene Ho, Majd T. Ghanim, Yichen Lu, Gregory Calip, Cleo Ryals, Jenny Guadamuz
Multi-Level Factors Underlying Racial/Ethnic Inequities in Clinical Trial Participation Among Patients with Hematologic Cancers: Lessons for the Development of Diversity Plans
Poster Presentation
Jenny Guadamuz, Harlan Pittell, Amy Pierre, Cleo Ryals, Gene Ho, Gregory Calip
